Melphalan

證據等級: L5

預測適應症: 10 個

Melphalan: From Multiple Myeloma to Gonadal Germ Cell Tumor

One-Sentence Summary

Melphalan is a bifunctional alkylating agent with established use in multiple myeloma and haematopoietic stem cell transplantation conditioning. The TxGNN model predicts it may be effective for Gonadal Germ Cell Tumor, with 8 clinical trials and 4 publications currently supporting this direction. Evidence is anchored by a completed Phase 2 trial directly targeting melphalan-containing high-dose chemotherapy in relapsed germ cell tumours, placing overall support at Level L2.

Quick Overview

Item	Content
Original Indication	Multiple myeloma and haematologic malignancies (established international use; not currently authorised in Denmark)
Predicted New Indication	Gonadal Germ Cell Tumor
TxGNN Prediction Score	99.77%
Evidence Level	L2
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Melphalan (L-phenylalanine mustard) belongs to the nitrogen mustard class of alkylating agents. It exerts its cytotoxic effect by forming DNA interstrand crosslinks (ISC), which physically block the replication fork and prevent transcription, ultimately triggering apoptosis in rapidly dividing cells. This mechanism is precisely why melphalan has long been the backbone of high-dose conditioning regimens before autologous stem cell transplantation (ASCT) — the DNA damage inflicted is severe enough to ablate the bone marrow, necessitating stem cell rescue.

Gonadal germ cell tumours (GCTs) are among the most chemotherapy-sensitive solid tumours in clinical oncology. First-line BEP (bleomycin, etoposide, cisplatin) cures the majority of patients, but platinum-refractory or relapsed disease represents a significant unmet need. In this salvage setting, high-dose chemotherapy (HDC) combined with ASCT is an established strategy to overcome platinum resistance. Because melphalan’s mechanism of action — DNA crosslinking via the alkylating pathway — is mechanistically distinct from platinum-based crosslinks, it offers a non-cross-resistant route to cytotoxicity, making it a rational partner in salvage HDC regimens for cisplatin-refractory GCT.

This rationale has been tested clinically. The GD-HDCT regimen (gemcitabine + docetaxel + melphalan + carboplatin), studied in a completed Phase 2 trial (NCT00936936, n=64) specifically in poor-prognosis relapsed GCT, represents the strongest direct evidence for this repurposing prediction and demonstrates that the TxGNN model is capturing a biologically and clinically plausible signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00936936	Phase 2	Completed	64	Two-cycle HDC regimen for poor-prognosis relapsed GCT: Cycle 1 = gemcitabine + docetaxel + melphalan + carboplatin; Cycle 2 = ifosfamide + carboplatin + etoposide. Only completed Phase 2 trial directly targeting relapsed GCT with a melphalan-containing regimen — the core evidence for this indication.
NCT00060255	Phase 2	Completed	451	Eight HDC regimens ± TBI prior to ASCT in haematologic malignancies and selected solid tumours; GCT was a common enrolled tumour type. Large Phase 2 dataset provides safety and feasibility data for ASCT-based approaches relevant to GCT.
NCT00536601	NA	Completed	174	Pilot trial comparing HDC regimens ± total-body irradiation before ASCT in haematologic cancers and solid tumours; provides safety data applicable to the GCT transplant setting.
NCT00638898	Phase 1	Completed	25	HDC with busulfan + melphalan + topotecan followed by ASCT in advanced and recurrent solid tumours including GCT; evaluates dose-safety of this melphalan-containing combination.
NCT00003425	Phase 1/2	Completed	25	Dose-escalation trial of high-dose melphalan with ASCT and amifostine cytoprotection; directly evaluates melphalan pharmacology, maximum tolerated dose, and tolerability across cancer types.
NCT01272817	NA	Completed	36	Nonmyeloablative allogeneic HSCT using antithymocyte globulin with melphalan and cladribine or total lymphoid irradiation for haematologic malignancies; provides reference safety data for melphalan in conditioning.
NCT00003926	Phase 1	Terminated	13	Amifostine chemoprotection with ASCT in paediatric solid tumours; terminated early (n=13), melphalan as carrier agent rather than primary study drug — limited evidentiary value.
NCT00002750	Phase 1	Completed	6	Intrathecal melphalan for recurrent neoplastic meningitis; route-specific study, not relevant to systemic GCT treatment; included for completeness only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
4270380	1973	Clinical Study	Oncology	Early systematic clinical experience with chemotherapy — including alkylating agents — in testicular germinal tumours; provides historical basis for melphalan in GCT.
24913	1977	Clinical Review	Urologic Clinics of North America	Review of seminoma management including cytotoxic chemotherapy options; contextualises the use of alkylating agents in gonadal GCT before platinum-based regimens became standard.
13392619	1956	Case Series	Voprosy Onkologii	Among the earliest documented use of sarcolysin (melphalan) for seminoma of the testes and its metastases; historical proof-of-concept for melphalan activity in GCT.
14151951	1964	Mechanistic Study	Acta — Unio Internationalis Contra Cancrum	Mechanistic investigation of alkylating drug effects on pituitary follicle-stimulating function; provides indirect mechanistic context for melphalan’s endocrine effects in gonadal tumour treatment.

Denmark Market Information

Melphalan currently holds no marketing authorisations in Denmark — neither via the Danish Medicines Agency (Lægemiddelstyrelsen) national procedure nor via the EMA centralised procedure. The drug is not commercially available on the Danish market.

Healthcare professionals seeking access for individual patients would need to apply through the named-patient (enkeltpatient) or compassionate-use pathway administered by Lægemiddelstyrelsen. Internationally, melphalan is authorised under the brand name Alkeran in numerous countries for multiple myeloma and as a conditioning agent prior to ASCT.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Nitrogen mustard / Alkylating agent (bifunctional)
Myelosuppression Risk	High — severe, dose-limiting myelosuppression (neutropenia, thrombocytopenia, anaemia) is the primary and expected toxicity; high-dose regimens require mandatory ASCT support for haematopoietic rescue
Emetogenicity Classification	Low to moderate (oral standard-dose); moderate to high (intravenous high-dose regimens)
Monitoring Items	Full blood count (CBC) with differential and platelets — frequent monitoring required; serum creatinine and eGFR (melphalan clearance is renally influenced); liver function tests (ALT, AST, bilirubin); electrolytes; mucositis assessment; long-term surveillance for secondary malignancy (AML/MDS)
Handling Protection	Must comply with cytotoxic drug handling regulations; appropriate PPE (gloves, gown, eye protection) required during preparation and administration; dedicated cytotoxic preparation area required

Safety Considerations

Detailed warnings, contraindications, and drug–drug interaction data were not available in the current evidence pack. Please refer to the approved Summary of Product Characteristics (SmPC) for complete safety information.

Clinical note for Danish practitioners: Melphalan is known to carry significant long-term risks, including secondary acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) with cumulative use, pulmonary toxicity, reproductive toxicity (gonadotoxicity), and teratogenicity. These risks are particularly relevant when considering use in younger GCT patients. A formal risk–benefit assessment and specialist MDT review are strongly recommended before initiating treatment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN model’s prediction of melphalan utility in gonadal germ cell tumour (score 99.77%) is biologically well-founded and supported by a completed Phase 2 clinical trial (NCT00936936, n=64) that directly evaluated a melphalan-containing HDC regimen in poor-prognosis relapsed GCT — meeting L2 evidence criteria. The drug’s DNA alkylating mechanism is non-cross-resistant with platinum, providing a sound scientific rationale for salvage use in platinum-refractory disease, a setting with limited alternatives in Denmark.

To proceed, the following is needed:

Regulatory access: Submit a named-patient or compassionate-use application to Lægemiddelstyrelsen, as melphalan is not marketed in Denmark
Safety documentation: Retrieve the full SmPC (warnings, contraindications, DDI profile) — this is a Blocking data gap in the current evidence pack
MOA confirmation: Obtain complete mechanism of action data from DrugBank to finalise the mechanistic analysis and support the clinical rationale document
Patient population definition: Restrict this indication to the evidence-supported population — platinum-refractory or relapsed GCT patients being considered for salvage HDC + ASCT in a specialist transplant centre
MDT review: Establish a haematology/oncology multidisciplinary team (MDT) review process; involve a transplant centre with ASCT capability before any clinical application
Prospective safety monitoring plan: Define specific monitoring parameters for myelosuppression, secondary malignancy surveillance, and organ function given the high-dose setting
Feasibility of trial enrolment: Assess whether Danish patients could be enrolled in an existing or planned international Phase 2/3 trial for relapsed GCT rather than off-label use

This report is generated for research reference purposes only and does not constitute medical advice. Repurposing candidates require clinical validation before therapeutic application. All pages referencing drug repurposing predictions should be understood in the context of investigational research.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.